middle.news
EVE Health Group Secures $0.9M to Boost Drug Reformulation Pipeline
9:48am on Friday 13th of March, 2026 AEDT
•
Healthcare
Read Story
EVE Health Group Secures $0.9M to Boost Drug Reformulation Pipeline
9:48am on Friday 13th of March, 2026 AEDT
Key Points
Raised $904,000 via placement to sophisticated investors
Funds to advance reformulated drug candidates in sexual health and cardiovascular markets
Focus on medicines approaching patent expiry using proprietary delivery technologies
Placement includes shares and attaching options exercisable at $0.04
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Eve Health (ASX:EVE)
OPEN ARTICLE